Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozorakimab - AstraZeneca

Next Previous
Drug Profile

Tozorakimab - AstraZeneca

Alternative Names: MEDI-3506

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca
  • Class Anti-inflammatories; Antiasthmatics; Antivirals; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease; Respiratory insufficiency
  • Phase II Asthma
  • Discontinued Atopic dermatitis; COVID 2019 infections; Diabetic nephropathies

Most Recent Events

  • 12 Apr 2025 AstraZeneca initiates enrolment in the phase-II COMETA trial for Chronic obstructive pulmonary disease (Treatment-experienced) in Russia (SC) (NCT06897748)
  • 07 Apr 2025 AstraZeneca plans phase I pharmacokinetic trial (In volunteers, In adults) (SC) (NCT06908577)
  • 28 Mar 2025 AstraZeneca plans phase-II COMETA trial for Chronic obstructive pulmonary disease (In adults, In the elderly, Treatment-experienced) in Russia (SC) (NCT06897748)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top